AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
38.23
-0.12 (-0.31%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close38.35
Open38.47
Bid0.00 x 800
Ask0.00 x 900
Day's Range38.07 - 38.59
52 Week Range32.69 - 41.78
Volume2,882,080
Avg. Volume4,558,249
Market Cap96.705B
Beta (3Y Monthly)0.66
PE Ratio (TTM)40.03
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.40 (3.58%)
Ex-Dividend Date2018-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal6 hours ago

    [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time

    China has for the first time approved a treatment from a global drugmaker before any other country, illustrating its recent push to bring in cutting-edge medicines—as well as Western companies’ growing interest in the market. The country’s medicines regulator on Tuesday approved roxadustat, a new anemia drug from AstraZeneca PLC and Fibrogen Inc., well ahead of any other nation. China approved 30 innovative drugs from foreign developers in the first nine months of this year—some taking just weeks—and, according to consulting firm McKinsey & Co., is on track to at least match last year’s 40 approvals, which marked the most by the regulator in any single year for at least a decade.

  • Why a kidney disease drug approval in China is just the start for this S.F. company
    American City Business Journals9 hours ago

    Why a kidney disease drug approval in China is just the start for this S.F. company

    After 25 years, FibroGen won its first drug approval, a treatment for anemia in chronic kidney disease patients in China. It hopes to follow that up with approvals in the United States, Japan and Europe over the next year.

  • BMY vs. AZN: Which Stock Should Value Investors Buy Now?
    Zacks17 hours ago

    BMY vs. AZN: Which Stock Should Value Investors Buy Now?

    BMY vs. AZN: Which Stock Is the Better Value Option?

  • Reuters20 hours ago

    China first to approve AstraZeneca, FibroGen anaemia drug

    China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.

  • Reuters20 hours ago

    China first to approve AstraZeneca, FibroGen anaemia drug

    China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.

  • Zacksyesterday

    Merck to Acquire Europe's Antelliq Group for $2.4 Billion

    Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.

  • How Is AstraZeneca Faring in Chinese Markets?
    Market Realist2 days ago

    How Is AstraZeneca Faring in Chinese Markets?

    How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis. China accounted for around 56% of the company’s total emerging markets sales and 19% of the total revenues earned by the company in the first nine months of 2018.

  • These New Products Are Driving AstraZeneca’s Growth in Fiscal 2018
    Market Realist2 days ago

    These New Products Are Driving AstraZeneca’s Growth in Fiscal 2018

    How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca reported oncology revenues of $4.26 billion, which is a YoY increase of 47% on an actual basis and 44% on a constant exchange rate (or CER) basis. In the first nine months of 2018, AstraZeneca reported new cardiovascular, renal, and metabolism (or CVRM) product sales worth $2.90 billion, which is a YoY rise of 14% on an actual basis and 12% on a CER basis.

  • What Are AstraZeneca’s Growth Drivers in Fiscal 2018?
    Market Realist5 days ago

    What Are AstraZeneca’s Growth Drivers in Fiscal 2018?

    How Is AstraZeneca Positioned in December? In the third quarter, AstraZeneca (AZN) managed to surpass consensus adjusted EPS estimates by $0.27. In the third quarter, AstraZeneca reported operating profit of $851 million, which is a YoY decline of 26% on an actual basis and 21% on a constant exchange rate (or CER) basis.

  • Zacks5 days ago

    Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

    AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

  • A Look at AstraZeneca’s Expense Projections for Fiscal 2018
    Market Realist5 days ago

    A Look at AstraZeneca’s Expense Projections for Fiscal 2018

    How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported selling, general, and administrative (or SG&A) expenses of $7.43 billion, which is a YoY rise of 4% on an actual basis and 1% on a constant exchange rate (or CER) basis. The company reported core SG&A expenses of $6.21 billion in the first nine months of 2018, which is a YoY rise of 10% on an actual basis and 7% on a CER basis.

  • What Are AstraZeneca’s Margin Projections for Fiscal 2018
    Market Realist5 days ago

    What Are AstraZeneca’s Margin Projections for Fiscal 2018

    How Is AstraZeneca Positioned in December? AstraZeneca (AZN) reported a gross margin of 79.8% in the first nine months of 2018, which is a decline of 200 basis points on a YoY basis. Wall Street analysts expect AstraZeneca to report a gross margin of 80.40% in fiscal 2018, which would be a YoY decline of 39 basis points.

  • What to Expect from AstraZeneca’s Earnings in Fiscal 2018
    Market Realist5 days ago

    What to Expect from AstraZeneca’s Earnings in Fiscal 2018

    How Is AstraZeneca Positioned in December? In its third-quarter earnings conference call, AstraZeneca (AZN) reiterated its core EPS guidance of $3.30–$3.50 at a constant exchange rate (or CER). In the third quarter, AstraZeneca posted core EPS of $0.71, which is a YoY decline of 37% on an actual basis and 33% on a CER basis.

  • What Analysts Recommend for AstraZeneca in December
    Market Realist6 days ago

    What Analysts Recommend for AstraZeneca in December

    How Is AstraZeneca Positioned in December? On December 11, AstraZeneca (AZN) closed at $38.66, which is 0.65% higher than its previous closing price. AstraZeneca has risen 3.40% from $38.51 on November 1 to $39.82 on November 30.

  • What’s the Market Opportunity for Zejula?
    Market Realist6 days ago

    What’s the Market Opportunity for Zejula?

    How Is Tesaro Positioned in December? As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication. GlaxoSmithKline (GSK) has estimated the annual incidence of these patients in the US market to be around 5,000.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of AZN.L earnings conference call or presentation 26-Jul-18 11:30am GMT

    Q2 2018 AstraZeneca PLC Earnings Call

  • A Look at Expansion Plans for Zejula
    Market Realist7 days ago

    A Look at Expansion Plans for Zejula

    On October 22, 2018, AstraZeneca (AZN) issued a press release announcing positive results from Phase 3 trial SOLO-1, which evaluated PARP inhibitor Lynparza as a first-line maintenance therapy in ovarian cancer patients with germline BRCA (or gBRCA) mutations. The robust data from this trial in terms of improvement in progression-free survival has made a strong case for the advancement of other PARP inhibitors in the maintenance setting for first-line ovarian cancer patients.

  • Here is What Hedge Funds Think About AstraZeneca plc (AZN)
    Insider Monkey7 days ago

    Here is What Hedge Funds Think About AstraZeneca plc (AZN)

    The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]

  • InvestorPlace8 days ago

    Moderna Stock Ushers In the Next Wave of Biotech

    Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.

  • Benzinga8 days ago

    Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

    Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...

  • Can Moderna Stock Recover From Its Initial Setback?
    Motley Fool8 days ago

    Can Moderna Stock Recover From Its Initial Setback?

    The largest biotech unicorn of its time is trying to get back up after stumbling out of the gate.

  • Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey10 days ago

    Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • New Biotech IPO Dropped a Unicorn-Sized Value on Its First Day
    Bloomberg11 days ago

    New Biotech IPO Dropped a Unicorn-Sized Value on Its First Day

    The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.